1201657-32-0

Basic information

• Product Name: 2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate
• Synonyms: 2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate;ethyl 2-Methyl-2-(4-(4;ethyl 2-Methyl-2-(4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate
• CAS NO: 1201657-32-0
• Molecular Formula: C15H25BN2O4
• Molecular Weight: 308.19
• Mol File: 1201657-32-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 406.2±25.0 °C(Predicted)
• Appearance: /
• Density: 1.08±0.1 g/cm3(Predicted)
• PKA: 1.53±0.10(Predicted)
• CAS DataBase Reference: 2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate(1201657-32-0)
• EPA Substance Registry System: 2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate(1201657-32-0)

Safety Data

• Hazardous Substances Data: 1201657-32-0(Hazardous Substances Data)

Usage

Description

2-Dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate, also known as Ethyl 2-Methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate, is a chemical compound that serves as a key reactant in the synthesis of pharmaceutical agents. It is characterized by its unique structure, which includes a dioxaborolan-2-yl group and a pyrazol-1-yl moiety, making it a versatile building block for the development of novel inhibitors.

Uses

Used in Pharmaceutical Industry:
2-Dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate is used as a reactant for the preparation of inhibitors that target the G1202R anaplastic lymphoma kinase resistance mutation. This mutation is associated with resistance to certain cancer therapies, and the development of inhibitors that can overcome this resistance is crucial for improving treatment outcomes for patients with anaplastic large cell lymphoma and other related cancers.
In the pharmaceutical industry, 2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate plays a significant role in the synthesis of novel compounds with potential therapeutic applications. Its unique structure allows for the design of inhibitors that can effectively target and overcome resistance mechanisms in cancer cells, leading to the development of more effective treatments for patients.

Upstream product

• 917569-72-3 2-(4-bromopyrazol-1-yl)-2-methylpropanoic acid 
• 1040377-17-0 ethyl 2-(4-bromo-1H-pyrazol-1-yl)-2-methylpropanoate 
• 73183-34-3 bis(pinacol)diborane 
• 600-00-0 ethyl 2-bromoisobutyrate 
• 851975-10-5 2-methyl-2-(1H-pyrazol-1-yl)propanoic acid 
• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 1022151-49-0 2-(4-iodo-pyrazol-1-yl)-2-methyl-propionic acid ethyl ester 

Downstream Products

• 1201653-86-2 N-(2-diethylamino-ethyl)-2-[4-(3-{3-[3-(2,2,2-trifluoro-ethyl)-ureido]-phenyl}-imidazo[1,2-a]pyridin-7-yl)-pyrazol-1-yl]-isobutyramide 
• 1201653-03-3 2-methyl-2-[4-(3-{3-[3-(2,2,2-trifluoroethyl)ureido]phenyl}imidazo[1,2-a]pyridin-7-yl)pyrazol-1-yl]propionic acid 
• 1201653-10-2 1-(3-{7-[1-(2-hydroxy-1,1-dimethylethyl)-1H-pyrazol-4-yl]-imidazo[1,2-a]pyridin-3-yl}phenyl)-3-(2,2,2-trifluoroethyl)urea 
• 1040377-18-1 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-yl)propan-1-ol 
• 1282513-03-4 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid 
• 1282512-48-4 taselisib 
• 1282514-64-0 ethyl 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoate 

Relevant articles and documents

Carbon-14 radiolabelling and tissue distribution evaluation of a potential anti-TB compound

This paper describes a five-step synthesis of a carbon-14-labelled pyrazole compound (11). A total of 2.96 MBq of 11 was obtained with the specific activity of 2242.4 MBq/mmol. The radiochemical purity was >99%, and the overall radiochemical yield was 60% based on the [14C6] 4-bromoaniline starting material. Biodistribution results showed that the radiotracer (administrated orally) has a high accumulation in the small intestine, large intestine and liver of both non-infected and tuberculosis (TB)-infected mice. Therefore, this suggests that compound 11 undergoes hepatobiliary clearance. The compound under investigation has been found to be slowly released from the liver between 2 and 8 h. The study revealed that 11 has no affinity for TB cells.

FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE

The present invention relates to a fused tricyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the present invention relates to a compound having Formula (I) or

DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

The present invention discloses a novel DGAT1 inhibitor, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof, preparation and pharmaceutical composition thereof, as well as their uses in the preparation of a medicament for the prevention and treatment of Familial hyperchylomicronemia (FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia.